R0-1 CA 50947/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2003	3
2004	2
2005	5
2006	3
2007	3
2008	4
2009	5
2011	2
2013	1
2024	0

1

Thalidomide and lenalidomide: Mechanism-based potential drug combinations.

Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC. Vallet S, et al. Leuk Lymphoma. 2008 Jul;49(7):1238-45. doi: 10.1080/10428190802005191. Leuk Lymphoma. 2008. PMID: 18452080 Review.

2

Recent advances in the treatment of Multiple Myeloma.

Yasui H, Hideshima T, Richardson PG, Anderson KC. Yasui H, et al. Curr Pharm Biotechnol. 2006 Oct;7(5):381-93. doi: 10.2174/138920106778521569. Curr Pharm Biotechnol. 2006. PMID: 17076653 Review.

3

Emerging therapies for multiple myeloma.

Podar K, Tai YT, Hideshima T, Vallet S, Richardson PG, Anderson KC. Podar K, et al. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. doi: 10.1517/14728210802676278. Expert Opin Emerg Drugs. 2009. PMID: 19249983 Free PMC article. Review.

4

Identification and validation of novel therapeutic targets for multiple myeloma.

Hideshima T, Chauhan D, Richardson P, Anderson KC. Hideshima T, et al. J Clin Oncol. 2005 Sep 10;23(26):6345-50. doi: 10.1200/JCO.2005.05.024. J Clin Oncol. 2005. PMID: 16155018 Review.

5

Bone marrow microenvironment and the identification of new targets for myeloma therapy.

Podar K, Chauhan D, Anderson KC. Podar K, et al. Leukemia. 2009 Jan;23(1):10-24. doi: 10.1038/leu.2008.259. Epub 2008 Oct 9. Leukemia. 2009. PMID: 18843284 Free PMC article. Review.

6

New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.

Cea M, Cagnetta A, Gobbi M, Patrone F, Richardson PG, Hideshima T, Anderson KC. Cea M, et al. Curr Pharm Des. 2013;19(4):734-44. Curr Pharm Des. 2013. PMID: 23016853 Free PMC article. Review.

7

Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma.

Hideshima T, Richardson PG, Anderson KC. Hideshima T, et al. Mol Cancer Ther. 2011 Nov;10(11):2034-42. doi: 10.1158/1535-7163.MCT-11-0433. Mol Cancer Ther. 2011. PMID: 22072815 Free PMC article. Review.

8

Targeting proteasome inhibition in hematologic malignancies.

Hideshima T, Richardson PG, Anderson KC. Hideshima T, et al. Rev Clin Exp Hematol. 2003 Jun;7(2):191-204. Rev Clin Exp Hematol. 2003. PMID: 14763162 Review.

9

Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications.

Hideshima T, Chauhan D, Kiziltepe T, Ikeda H, Okawa Y, Podar K, Raje N, Protopopov A, Munshi NC, Richardson PG, Carrasco RD, Anderson KC. Hideshima T, et al. Blood. 2009 May 21;113(21):5228-36. doi: 10.1182/blood-2008-06-161505. Epub 2009 Mar 6. Blood. 2009. PMID: 19270264 Free PMC article.

10

Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.

Raje N, Woo SB, Hande K, Yap JT, Richardson PG, Vallet S, Treister N, Hideshima T, Sheehy N, Chhetri S, Connell B, Xie W, Tai YT, Szot-Barnes A, Tian M, Schlossman RL, Weller E, Munshi NC, Van Den Abbeele AD, Anderson KC. Raje N, et al. Clin Cancer Res. 2008 Apr 15;14(8):2387-95. doi: 10.1158/1078-0432.CCR-07-1430. Clin Cancer Res. 2008. PMID: 18413829

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

27 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Results by year